CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02498613
Title field or adapter rule: {'original_value': 'A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors', 'source_field': 'protocolSection.identificationModule.officialTitle'}
Ingested At: 2026-10-31T23:27:24.872174+00:00
Published At: 2024-07-30T00:00:00+00:00
Record Updated At: 2026-09-25
Results Posted At: 2024-07-30
Source Retrieved At: 2026-10-31T22:17:54.613222+00:00
Timestamp Basis: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter
Date limitation: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions: ["Advanced Malignant Solid Neoplasm", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Lung Small Cell Carcinoma", "Metastatic Pancreatic Adenocarcinoma", "Metastatic Triple-Negative Breast Carcinoma", "Pancreatic Ductal Adenocarcinoma", "Stage III Breast Cancer AJCC v7", "Stage III Lung Non-Small Cell Cancer AJCC v7", "Stage III Lung Small Cell Carcinoma AJCC v7", "Stage III Pancreatic Cancer AJCC v6 and v7", "Stage IIIA Breast Cancer AJCC v7", "Stage IIIA Lung Non-Small Cell Cancer AJCC v7", "Stage IIIA Lung Small Cell Carcinoma AJCC v7", "Stage IIIB Breast Cancer AJCC v7", "Stage IIIB Lung Non-Small Cell Cancer AJCC v7", "Stage IIIB Lung Small Cell Carcinoma AJCC v7", "Stage IIIC Breast Cancer AJCC v7", "Stage IV Breast Cancer AJCC v6 and v7", "Stage IV Lung Non-Small Cell Cancer AJCC v7", "Stage IV Lung Small Cell Carcinoma AJCC v7", "Stage IV Pancreatic Cancer AJCC v6 and v7", "Triple-Negative Breast Carcinoma", "Unresectable Lung Small Cell Carcinoma", "Unresectable Pancreatic Adenocarcinoma", "Unresectable Pancreatic Carcinoma", "Unresectable Triple-Negative Breast Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct: {"date": "2026-09-25", "type": "ACTUAL"}
protocolSection.identificationModule.nctId: "NCT02498613"
protocolSection.identificationModule.officialTitle: "A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct: {"date": "2024-07-30", "type": "ACTUAL"}

Study condition terms

Interventions recorded in this study

{'armGroupLabels': ['Treatment (cediranib maleate, olaparib)'], 'description': 'Correlative studies', 'name': '18F-Fluoromisonidazole', 'type': 'OTHER'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Treatment (cediranib maleate, olaparib)'], 'description': 'Given PO', 'name': 'Cediranib Maleate', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Treatment (cediranib maleate, olaparib)'], 'description': 'Correlative studies', 'name': 'Laboratory Biomarker Analysis', 'type': 'OTHER'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Treatment (cediranib maleate, olaparib)'], 'description': 'Given PO', 'name': 'Olaparib', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Treatment (cediranib maleate, olaparib)'], 'description': 'Correlative studies', 'name': 'Positron Emission Tomography', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.